RxDoctor Payments DataLook up a doctor →

Robert Davis, MD

Internal Medicine · Corvallis, ORNPI 1629481452

Payments from drug & device makers

$164,812in general payments, 2019–2025

Across 200 payments — averaging $824.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$159K
  • AstraZeneca$777
  • Astellas Pharma US Inc$534
  • E.r. Squibb & Sons, L.L.C.$301
  • Janssen Scientific Affairs, LLC$285
  • Gilead$271
  • plus $4K from 54 others
$36in research payments, 2019–2025

Across 2 payments — averaging $17.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$36

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly5$159,069
AstraZeneca(2 entities)23$777
Astellas Pharma US Inc10$534
E.r. Squibb & Sons, L.L.C.9$301
Janssen Scientific Affairs, LLC3$285
Gilead(2 entities)7$271
Tempus AI, Inc4$262
Novartis14$249
Pfizer9$233
Daiichi Sankyo Inc.4$220
Johnson & Johnson8$200
Bayer10$176
Lilly USA, LLC10$159
Eisai Inc.6$153
Merck6$148
AVEO Pharmaceuticals, Inc.6$126
Stemline Therapeutics Inc.4$118
Amgen4$112
Genentech USA, Inc.3$112
AbbVie4$108
Mirati Therapeutics, Inc.2$101
Sanofi3$83
Pharmaessentia USA Corporation2$60
Dendreon Pharmaceuticals LLC2$54
Bristol Myers Squibb1$46
Sobi, Inc2$43
EMD Serono, Inc.2$42
Coherus Oncology, Inc.1$40
Regeneron Healthcare Solutions, Inc.2$38
Ipsen Biopharmaceuticals, Inc2$36
Genmab U.S., Inc.1$34
Takeda Pharmaceuticals U.S.A., Inc.2$33
Karyopharm Therapeutics Inc.2$32
GSK1$29
Sumitomo Pharma America, Inc.1$29
Organon1$29
Rigel Pharmaceuticals, Inc.1$28
Sun Pharmaceutical Industries Inc.1$27
G1 Therapeutics, Inc.1$24
Deciphera Pharmaceuticals Inc.1$24
Adaptive Biotechnologies Corporation1$23
Blueprint Medicines Corporation1$23
Morphosys, US Inc.1$22
Agios Pharmaceuticals, Inc.1$22
Incyte Corporation1$21
Puma Biotechnology, Inc.1$20
Kyowa Kirin, Inc.1$19
Acrotech Biopharma Inc.1$18
Iovance Biotherapeutics, Inc.1$18
Boehringer Ingelheim1$18
Foundation Medicine, Inc.1$18
Alnylam Pharmaceuticals Inc.1$17
Jazz Pharmaceuticals Inc.1$17
Spectrum Pharmaceuticals Inc.1$17
Myriad Genetic Laboratories, Inc.1$16
Pharmacyclics LLC, An Abbvie Company1$16
Tersera Therapeutics LLC1$16
Array Biopharma Inc1$15
Beone Medicines USA, Inc.1$14
Geron Corporation1$14

How this compares

$164,812 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.

See all internal medicine providers in Oregon →

Medicare billing

Part B allowed, 2024
$68,297
Medicare patients
202
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Corvallis

See the full list for Oregon →

Where these figures come from

Is this you, or does something look wrong? →